Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $66.00

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $63.00.

A number of brokerages have recently issued reports on CLDX. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Friday, March 22nd. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday, June 3rd. Guggenheim boosted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, Wolfe Research began coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective on the stock.

Get Our Latest Stock Report on Celldex Therapeutics

Celldex Therapeutics Trading Up 0.7 %

NASDAQ CLDX opened at $34.91 on Tuesday. The business’s 50-day moving average price is $37.66 and its two-hundred day moving average price is $39.04. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The firm has a market capitalization of $2.30 billion, a PE ratio of -12.25 and a beta of 1.48.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. As a group, analysts forecast that Celldex Therapeutics will post -2.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Elizabeth Crowley sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the transaction, the vice president now directly owns 9,074 shares of the company’s stock, valued at approximately $318,134.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, VP Elizabeth Crowley sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the transaction, the vice president now directly owns 9,074 shares of the company’s stock, valued at approximately $318,134.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Richard M. Wright sold 46,844 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $33.72, for a total value of $1,579,579.68. Following the transaction, the vice president now directly owns 20,833 shares in the company, valued at $702,488.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 219,160 shares of company stock valued at $7,501,489. 3.80% of the stock is owned by company insiders.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Strs Ohio raised its stake in shares of Celldex Therapeutics by 92.9% in the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics in the first quarter worth approximately $147,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of Celldex Therapeutics in the fourth quarter worth approximately $251,000. Finally, Panoramic Investment Advisors LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter valued at approximately $258,000.

About Celldex Therapeutics

(Get Free Report

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

See Also

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.